Visualizing TGF-ß and BMP signaling in human atherosclerosis: A histological evaluation based on Smad activation

Histology and Histopathology

Volumn 27, Issue 3, 2012, Pages 387-396

  van Dijk, R A ^a   Engels, C C ^a   Schaapherder, A F ^a   Mulder Stapel, A ^a   ten Dijke, P ^a   Hamming, J F ^a   Lindeman, J H N ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aorta; Atherosclerosis; BMP signaling; Inflammation; TGF signaling

Indexed keywords

BONE MORPHOGENETIC PROTEIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ADULT; AGED; AORTA; AORTA DISEASE; ARTICLE; ATHEROSCLEROSIS; CASE CONTROL STUDY; CHILD; DISEASE COURSE; FEMALE; HEALTH CARE FACILITY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MACROPHAGE; MALE; METABOLISM; MIDDLE AGED; NETHERLANDS; PATHOLOGY; PHOSPHORYLATION; PRESCHOOL CHILD; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; AORTA; AORTIC DISEASES; ATHEROSCLEROSIS; BONE MORPHOGENETIC PROTEINS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MIDDLE AGED; NETHERLANDS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMAD PROTEINS; T-LYMPHOCYTES; TISSUE BANKS; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 84857771580     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bobik A. (2006). Transforming growth factor-ßs and vascular disorders. Arterioscler. Thromb. Vasc. Biol. 26, 1712-1720.
2. Bot P.T.G., Hoefer I.E., Sluijter J.P.G., van Vliet P., Smits A.M., Lebrin F., Moll F., de Vries J.P., Doevendans P., Piek J.J., Pasterkamp G. and Goumans M.J. (2009). Increased expression of the transforming growth factor-ß signaling pathway, endoglin, and early growth response-1 in stable plaques. Stroke 40, 439-447.
3. Dennler S., Itoh S., Vivien D., Ten Dijke P., Huet S. and Gauthier J.M. (1998). Direct binding of Smad3 and Smad4 to critical TGF betainducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17, 3091-3100.
4. de Sousa Lopes S.M., Carvalho R.L., van den Driesche S., Goumans M.J., Ten Dijke P. and Mummery C.L. (2003). Distribution of phosphorylated Smad2 identifies target tissues of TGF beta ligands in mouse development. Gene Expressions Patterns 3, 355-360.
5. Engelse M.A., Neele J.M., van Achterberg T.A.E., van Aken B.E., van Schaik R.H.N., Pannekoek H. and de Vries C.J. (1999). Human activin-A is expressed in the atherosclerotic lesion and promotes the contractile phenotype of smooth muscle cells. Circ. Res. 85, 931-939.
6. Frutkin A.D., Otsuka G., Stempien-Otero A., Sesti C., Du L., Jaffe M., Dichek H.L., Pennington C.J., Edwards D.R., Nieves-Cintrón M., Minter D., Preusch M., Hu J.H., Marie J.C. and Dichek D.A. (2009). TGF-ß 1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 29, 1251-1257.
7. Gojova A., Brun V., Esposito B., Cottrez F., Gourdy P., Ardouin P., Tedgui A., Mallat Z. and Groux H. (2003). Specific abrogation of transforming growth factor-ß signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood 102, 4052-4058.
8. Grainger D.J. (2004). Transforming growth factor ß and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler. Thromb. Vasc. Biol. 24, 399-404.
9. Grainger D.J. (2007). TGF-ß and atherosclerosis in man. Cardiovasc. Res. 74, 213-222.
10. Grainger D.J., Kemp P.R., Metcalfe J.C., Liu A.C., Lawn R.M., Williams N.R., Grace A.A., Schofield P.M. and Chauhan A. (1995a). The serum concentration of active transforming growth factor-ß is severely depressed in advanced atherosclerosis. Nature Med. 1, 74-79.
11. Grainger D.J., Wakefield L., Bethell H.W., Farndale R.W. and Metcalfe J.C. (1995b). Release and activation of platelet latent TGF-ß in blood clots during dissolution with plasmin. Nature Med. 1, 932-937.
12. Hansson G.K. (2001). Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21, 1876-1890.
13. Heldin C.H., Miyazono K. and Ten Dijke P. (1997). TGF-ß signalling from cell membrane to nucleus through SMAD proteins. Nature 390, 465-471.
14. Kalinina N., Agrotis A., Antropova Y., Ilyinskaya O., Smirnov V., Tararak E. and Bobik A. (2004). Smad expression in human atherosclerotic lesions: Evidence for impaired TGF-ß/Smad signaling in smooth muscle cells of fibrofatty lesions. Arterioscler. Thromb. Vasc. Biol. 24, 1391-1396.
15. Lakos G., Takagawa S., Chen S.J., Ferreira A.M., Han G., Masuda K., Wang X.J., DiPietro L.A and, Varga J. (2004). Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am. J. Pathol. 165, 203-217.
16. Leonarduzzi G., Sevanian A., Sottero B., Arkan M.C., Biasi F., Chiarpotto E., Basaga H. and Poli G. (2001). Up-regulation of the fibrogenic cytokine TGF-ß 1 by oxysterols: a mechanistic link between cholesterol and atherosclerosis. FASEB J. 15, 1619-1621.
17. Lindeman J.H.N., Pijl H., Toet K., Eilers P.H.C., van Ramshorst B. and Buijs M.M. (2007). Human visceral adipose tissue and the plasminogen activator inhibitor type 1. Int. J. Obesity. 31, 1671-1679.
18. Lutgens E., Gijbels M., Smook M., Heeringa P., Gotwals P., Koteliansky V.E. and Daemen E.J. (2002). Transforming growth factor-ß mediates balance between inflammation and fibrosis during plaque progression. Arterioscler. Thromb. Vasc. Biol. 22, 975-982.
19. Mallat Z. and Tedgui A. (2002). The role of transforming growth factor ' in atherosclerosis: novel insights and future perspectives. Curr. Opin. Lipidol. 13, 523-529.
20. Mallat Z., Gojova A., Marchiol-Fournigault C., Esposito B., Kamate C., Merval R., Fradelizi D. and Tedgui A. (2001). Inhibition of transforming growth factor-' signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circulation Res. 89, 930-934.
21. Mehta J.L. and Attramadal H. (2007). The TGF superfamily in cardiovascular biology. Cardiovascular Res. 74, 181-183.
22. Negishi M., Lu D., Zhang Y.Q., Sawada Y., Sasaki T., Kayo T., Ando J., Izumi T., Kurabayashi M., Kojima I., Masuda H. and Takeuchi T. (2001). Upregulatory expression of Furin and Transforming Growth Factor-ß by fluid shear stress in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 21, 785-790.
23. Persson U., Izumi H., Souchelnytskyi S., Itoh S., Grimsby S., Engström U., Heldin C.H., Funa K. and Ten Dijke P. (1998). The L45 loop in type I receptors for TGF-beta family members is a critical determinant in specifying Smad isoform activation. FEBS Lett. 434, 83-87.
24. Redondo S., Santos-Gallego C.G. and Tejerina T. (2006). TGF-ß1: a novel target for cardiovascular pharmacology. Cytokine Growth Factor Rev. 18, 279-286.
25. Shimada K. (2009). Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circulation J. 73, 994-1001.
26. Singh N.N. and Ramji D.P. (2006). The role of transforming growth factor-ß in atherosclerosis. Cytokine Growth Factor Rev. 17, 487-499.
27. Smith C., Yndestad A., Halvorsen B., Ueland T., Waehre T., Otterdal K., Scholz H., Endresen K., Gullestad L., Frøland S.S., Damås J.K. and Aukrust P. (2004). Potential anti-inflammatory role of activin A in acute coronary syndromes. J. Am. Cell. Cardiol. 44, 369-375.
28. Spencer M., Yao-Borengasser A., Unal R., Rasouli N., Gurley C.M., Zhu B., Peterson C.A. and Kern P.A. (2010). Adipose tissue macrophages in insulin resistant subjects are associated with collagen VI, fibrosis and demonstrate alternative activation. Am. J. Physiol. Endocrinol. Metabol. 299, 1016-1027.
29. Stary H.C., Blankenhorn D.H., Chandler A.B., Glagov S., Insull Jr W., Richardson M., Rosenfelt M.E., Schaffer S.A., Schwartz C.J., Wagner W.D. and Wissler R.W. (1992). A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler. Thromb. Vasc. Biol. 12, 120-134.
30. van Dijk R.A., Virmani R., von der Thüsen J.H., Schaapherder A.F. and Lindeman J.H.N. (2010). The natural history of aortic atherosclerosis: a systematic histopathological evaluation of the peri-renal region. Atherosclerosis 210,100-106.
31. Vaughan D.E. (2006). PAI-1 and TGF-ß: Unmasking the real driver of TGF-ß induced vascular pathology. Arterioscler. Thromb. Vasc. Biol. 26, 679-680.
32. Virmani R., Kolodgie F.D., Burke A.P., Farb A. and Schwartz SM. (2000). Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20, 1262-1275.
33. Volger O.L., Fledderus J.O., Kisters N., Fontijn R.D., Moerland P.D., Kuiper J., van Berkel T.J., Bijnens A.P., Daemen M.J., Pannekoek H. and Horrevoets A.J. (2007). Distinctive expression of chemokines and transforming growth factor-ß signaling in human arterial endothelium during atherosclerosis. Am. J. Pathol. 171, 326-337.
34. Wang X.L., Liu S.X. and Wilcken D.E.L. (1997). Circulating transforming growth factor 1 and coronary artery disease. Cardiovasc. Res. 34, 404-410.
35. Yamada R., Suzuki T., Hashimoto M., Eto Y., Shiokawa K. and Muramatsu M. (1992). Induction of differentiation of the human promyelocytic cell line HL-60 by activin/EDF. Biochem. Biophys. Res. Commun. 187, 79-85.